Your trusted source for investing success

Tag: Ovarian Cancer

DelMar Pharmaceuticals Receives Approval from China’s Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM

DelMar Pharmaceuticals Receives Approval from China’s Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the Human Genetic Resources Administration of China (HGRAC), has approved the Company’s application to initiate a Phase 2 safety and efficacy study of its lead product candidate VAL-083 in newly diagnosed MGMT-unmethylated glioblastoma

DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced the completion of the first site initiation visit at the Dent Neurological Institute (“Dent”) for its pivotal Phase 3 Study in Temozolomide-Avastin (bevacizumab) Recurrent GBM (“STAR-3”).  Site initiation visits are generally the final step before patient enrollment.

The

DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced it has received Institutional Review Board (IRB) approval to conduct its pivotal Phase 3 Study in Temozolomide-Avastin (bevacizumab) Recurrent GBM (STAR-3).

“IRB approval is an essential step in initiating patient enrollment in our

DelMar Presents Poster of Clinical Research with VAL-083 in Patients with Chemo-resistant Glioblastoma (“GBM”) at SNO’s Pediatric Neuro-Oncology Basic and Translational Research Conference

DelMar Presents Poster of Clinical Research with VAL-083 in Patients with Chemo-resistant Glioblastoma (“GBM”) at SNO’s Pediatric Neuro-Oncology Basic and Translational Research Conference

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of unique new cancer therapies designed to save and improve lives, announced today the presentation of a poster at The Society for Neuro-Oncology’s 4th Pediatric Neuro-Oncology Basic and Translational Research Conference. The forum takes place at the Wyndham

DelMar Presents New Mechanism of Action Data for its Lead Agent VAL-083 in Temozolomide-Resistant Glioblastoma Multiforme (GBM) at the World Federation of Neuro-Oncology Societies (WFNOS)

DelMar Presents New Mechanism of Action Data for its Lead Agent VAL-083 in Temozolomide-Resistant Glioblastoma Multiforme (GBM) at the World Federation of Neuro-Oncology Societies (WFNOS)

DelMar Pharmaceuticals (NASDAQ:DMPI), a biopharmaceutical company focused on developing new cancer therapies, today announced new mechanism of action (MOA) data for its anti-cancer product candidate, VAL-083 (dianhydrogalactitol), a “first-in-class” small-molecule DNA-targeting agent in temozolomide (Temodar™)-resistant GBM, at the World Federation of Neuro-Oncology Societies (WFNOS).

DelMar Pharmaceuticals Collaborates with Duke University to Explore VAL-083 as a Front-Line Treatment for Glioblastoma Multiforme

DelMar Pharmaceuticals Collaborates with Duke University to Explore VAL-083 as a Front-Line Treatment for Glioblastoma Multiforme

DelMar Pharmaceuticals (NASDAQ:DMPI), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it has entered into a three-year collaboration with Duke University to evaluate VAL-083, the Company’s platform compound, as a front-line treatment for newly diagnosed patients with glioblastoma multiforme (“GBM”).

Enter Your Log In Credentials
×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network